LDZA Stock Overview
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Aspen Pharmacare Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R9.75 |
| 52 Week High | R12.70 |
| 52 Week Low | R7.90 |
| Beta | 0.69 |
| 11 Month Change | -16.67% |
| 3 Month Change | -20.08% |
| 1 Year Change | 14.71% |
| 33 Year Change | -34.12% |
| 5 Year Change | 89.32% |
| Change since IPO | 190.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDZA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -3.0% | 0.2% |
| 1Y | 14.7% | -16.5% | 7.6% |
Return vs Industry: LDZA exceeded the German Pharmaceuticals industry which returned -16.5% over the past year.
Return vs Market: LDZA exceeded the German Market which returned 7.6% over the past year.
Price Volatility
| LDZA volatility | |
|---|---|
| LDZA Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LDZA's share price has been volatile over the past 3 months.
Volatility Over Time: LDZA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1850 | 8,887 | Stephen Saad | www.aspenpharma.com |
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names.
Aspen Pharmacare Holdings Limited Fundamentals Summary
| LDZA fundamental statistics | |
|---|---|
| Market cap | €4.42b |
| Earnings (TTM) | €228.35m |
| Revenue (TTM) | €2.32b |
19.4x
P/E Ratio1.9x
P/S RatioIs LDZA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDZA income statement (TTM) | |
|---|---|
| Revenue | R44.71b |
| Cost of Revenue | R25.25b |
| Gross Profit | R19.45b |
| Other Expenses | R15.05b |
| Earnings | R4.40b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.90 |
| Gross Margin | 43.52% |
| Net Profit Margin | 9.85% |
| Debt/Equity Ratio | 43.0% |
How did LDZA perform over the long term?
See historical performance and comparison